A study published in The New England Journal of Medicine examining rituximab in membranous nephropathy found that it is noninferior to cyclosporine in inducing proteinuria remission at 12 months and is superior to maintaining long-term remission up to 24 months in patients at high risk for progressive disease.
A study published in The New England Journal of Medicine examining rituximab in membranous nephropathy found that it is noninferior to cyclosporine in inducing proteinuria remission at 12 months and is superior to maintaining long-term remission up to 24 months in patients at high risk for progressive disease.1
Membranous nephropathy, an incurable kidney disease sometimes associated with autoimmune diseases or diabetes, is the leading cause of nephrotic syndrome in adults, where an excess of protein is deposited in urine as capillaries in the kidney become damaged.
In an accompanying editorial, the authors noted that the discovery of rituximab for this condition was first made about 20 years ago, but despite what they called “one of the most important findings” of this trial—a large difference between the rituximab group and the cyclosporine group regarding the percentage of patients with complete remission (35% vs none)—they said it is not likely that rituximab will become a top treatment for all patients with this disease.2 Rituximab may fail in 25% to 30% of patients with nephrotic syndrome, because of ineffective or transient depletion of nephritogenic antibodies or sensitization syndrome, leading to treatment resistance.
The Membranous Nephropathy Trial of Rituximab (MENTOR) was a prospective, randomized, open-label, noninferiority trial conducted at 22 sites in North America with 130 patients. Since B-cell irregularities play a role in membranous nephropathy, researchers theorized that B-cell depletion with rituximab may be noninferior to treatment with cyclosporine for inducing and maintaining a complete or partial remission of proteinuria.
Patients who had membranous nephropathy, proteinuria of at least 5 g per 24 hours, and a quantified creatinine clearance of at least 40 mL per minute per 1.73 m2 of body-surface area and had been receiving angiotensin-system blockade for at least 3 months were randomized to receive rituximab (2 infusions, 1000 mg each, administered 14 days apart; repeated at 6 months in case of partial response) or oral cyclosporine (starting at a dose of 3.5 mg per kilogram of body weight per day for 12 months).
The primary outcome for patients, who were followed for 24 months, was a composite of complete or partial remission of proteinuria at 24 months.
At 12 months, 39 of 65 patients (60%) in the rituximab group and 34 of 65 (52%) in the cyclosporine group had a complete or partial remission (risk difference, 8 percentage points; 95% CI, —9 to 25; P = .004 for noninferiority).
At 24 months, 39 patients (60%) in the rituximab group and 13 (20%) in the cyclosporine group had a complete or partial remission (risk difference, 40 percentage points; 95% CI, 25 to 55; P <.001 for both noninferiority and superiority). Among patients in remission who tested positive for antiphospholipase A2 receptor (PLA2R) antibodies, the decline in autoantibodies to anti-PLA2R was faster and of greater magnitude and duration in the rituximab group than in the cyclosporine group.
In addition, serious adverse events were fewer with rituximab: 11 patients (17%) , compared with 20 patients (31%) in the cyclosporine group (P = .06).
References
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
"Not So Different": How the BPCIA Transition Will Affect Biosimilar Uptake
April 10th 2020This week on the podcast, we’re speaking with the executive director of the Biologics and Biosimilars Collective Intelligence Consortium (BBCIC), Cate Lockhart, PharmD, PhD, about the acceptance process for biosimilars in the United States, what BBCIC is doing to help the market develop, and how the new approval pathway for biologics will affect the pace at which biosimilars come to market.
Analyzing Safety of Switching From Originators to Biosimilars: A Meta-Analysis of 21 Trials
February 10th 2024The authors of a meta-analysis assessing several disease states found no significant differences in serious adverse events, deaths, or treatment discontinuations between patients who switched from reference products to biosimilars and those who did not.
Report: Varied Biosimilar Uptake Speeds Pose Missed Opportunities for Cost Savings
January 23rd 2024Samsung Bioepis’ Biosimilar Market Report for the first quarter of 2024 chronicles some major market trends, including which treatment spaces have quicker uptake than others, highlighting missed opportunities for savings as well as the 1-year experience of adalimumab biosimilar competition in the US.
IQVIA Projects $192 Billion Loss for Originators by 2028 Thanks to Biosimilar, Generic Competition
January 18th 2024The IQVIA Institute for Human Data Science’s most recent Global Use of Medicines report projected that market introductions of new biosimilar and generic drugs will increase projected losses for originator products from $111 billion to $192 billion over the next 5 years.
IQVIA Report Flags Challenges With Biosimilar Access, Savings Throughout Europe
January 10th 2024IQVIA’s report on the impact biosimilar competition has had on Europe’s health care space identified ongoing challenges with biosimilar access and generating savings, calling for more policies focusing on fostering a sustainable market for years to come.